In October 2025, the FDA approved an updated label update for capecitabine mandating DPYD genetic testing before initiating treatment, unless urgent.
Serena Mitaly, PharmD
Advertisement
Articles by Serena Mitaly, PharmD
Serena Mitaly, PharmD, outlines how Ochsner Health is building a sustainable pharmacogenomics program by integrating clinical decision support tools into the EMR, educating providers, addressing reimbursement barriers, and expanding the role of PGx pharmacists in personalized medicine.
Major pharmacogenomics organizations continue to recognize the potential relevance of pharmacogenomics for psychiatric medication management, mainly due to its effects on pharmacokinetics.
Advertisement
Latest Updated Articles
From Warning to Action: Implementing DPYD Testing Following the FDA-Approved Capecitabine Label UpdatePublished: January 15th 2026 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
TrumpRx Launches, Offering Cash-Paying Patients Discounted Drugs
2
SGLT2 Inhibitors in T2D Lower 5-Year Risk of CKD and Acute Kidney Injury
3
Pharmacist Takeover: CAR T Therapy Signals a Shift in ALL Treatment
4
Balancing Survival and Quality of Life in Pancreatic Cancer: Expert Perspectives From an Immuneering Panel
5